Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | HTR1D | P28221 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | HTR5A | P47898 | 3/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | SYK | P43405 | 6/20 | 0.36 |
| ▸ | CD63 | P08962 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529319 | 0.84 | SYK (0.40) | HTR7HTR1AHTR1DHTR2AHTR2C | |
| SCHEMBL24529202 | 0.84 | TRIM33 (0.46) | HTR7HTR1AHTR1DHTR2AHTR2C | |
| SCHEMBL27179763 | 0.80 | KDM4E (0.38) | SYKCD63 | |
| SCHEMBL24529174 | 0.77 | ALDH1A1 (0.43) | SYKCD63 | |
| SCHEMBL24386988 | 0.76 | ALDH1A1 (0.38) | HTR7HTR1AHTR1DHTR2AHTR2C | |
| SCHEMBL24529207 | 0.72 | HDAC6 (0.37) | HTR1APDE4BSYKCD63HDAC6 | |
| SCHEMBL2890179 | 0.71 | SYK (0.68) | SYKCD63 | |
| SCHEMBL29723314 | 0.70 | HCRTR2 (0.43) | — | |
| SCHEMBL27180048 | 0.70 | HCRTR2 (0.43) | — | |
| SCHEMBL24529142 | 0.70 | HCRTR2 (0.46) | SYKCD63 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HTR7 99/4885HTR1A 102/4885HTR1D 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.